You are here

Final decisions and reasons for NCEs, medicines and chemicals, November 2018

Scheduling medicines and poisons

26 April 2019

Book pagination

4.2. Doravirine

Part B - Final decisions on matters not referred to an expert advisory committee

4. New Chemical Entities - medicines for human therapeutic use

4.2. Doravirine


New text is shown as green, larger font, with a horizontal line above it.

Delegate's final decision
Final decision

The delegate's final decision is to amend the Poisons Standard to include doravirine in Schedule 4 as follows:

Schedule 4 - New Entry


Index - New Entry


Schedule 4

Implementation date

1 June 2019


The matters under subsection 52E (1) of the Therapeutic Goods Act 1989 considered relevant by the delegate for the decision include:

  1. the risks and benefits of the use of a substance:

    It is a New Chemical Entity with no clinical or marketing experience in Australia. The risk-benefit requires appropriate selection of patients by the treating physician.

  2. the purposes for which a substance is to be used and the extent of use of a substance:

    Used in the treatment of a serious infection (HIV) requiring specialised medical oversight and monitoring.

  3. the toxicity of a substance:

    Doravirine is a HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI). Toxicity typical of NNRTI agents is expected. Drug interactions are also a safety concern.

  4. the dosage, formulation, labelling, packaging and presentation of a substance:

    Presentation and packaging consistent with the labelling requirements for prescription medicine.

  5. the potential for abuse of a substance:


  6. any other matters that the Secretary considers necessary to protect public health:


Scheduling proposal

The delegate of the Secretary proposed to amend the Poisons Standard with respect to doravirine, a new chemical entity (NCE) for a human therapeutic medicine.

Scheduling status

Doravirine is not specifically scheduled and is not captured by any entry in the Poisons Standard.

Delegate's considerations
  • Section 52E(1) of the Therapeutic Goods Act 1989;
  • Scheduling Policy Framework (SPF 2018); and
  • Advice on the place in therapy of this NCE.

Book pagination